Self-reported disability in women with fibromyalgia from a tertiary care center

Table 1 Socio-demographic and clinical variables of the 114 patients with disability

	Mild (n = 13)	Moderate (n = 54)	Severe (n = 47)	Total (n = 114)	P value	Size effect
Age in years	48.2 ± 5.9	49.9 ± 7.2	46.8 ± 6.4	48.4 ± 6.8	0.07	0.02^a
Years of education	10 ± 3.5	10.2 ± 3.6	10.1 ± 3.2	10.1 ± 3.4	0.98	0.01^a
Time since onset of pain (months)	48 (24)	48 (64)	36 (42)	48 (60)	0.22	0.02^b
Time since FM diagnosis (months)	36 (46)	34 (36)	12 (36)	24 (42)	0.08	0.03^b
Body mass index	29.1 ± 4.5	28.4 ± 3.1	28.9 ± 3.7	28.7 ± 3.5	0.72	0.01^a
Pain Intensity	5.0 ± 2.3	6.2 ± 2.1	7.3 ± 1.6	6.5 ± 2.1	< 0.001	0.12^a
Number of drugs	2.3 ± 1.1	2.12 ± 1.2	2.08 ± 1.2	2.1 ± 1.2	0.85	0.01^a
Pharmacological treatment	11 [84.6]	49 [90.7]	39 [82.9]	99 [86.8]	0.49	–
Celecoxib	5 [38.4]	21 [38.8]	9 [19.1]	35 [30.7]	0.08
Nonsteroidal anti-inflammatory drugs	3 [23.0]	9 [16.6]	13 [27.6]	25 [21.9]	0.41
Pregabalin or Gabapentin	6 [46.1]	30 [55.5]	24 [51.0]	60 [52.6]	0.79
Antidepressants	9 [69.2]	27 [50.0]	29 [61.7]	65 [57.0]	0.31
Tramadol-acetaminophen	5 [38.4]	19 [35.1]	13 [27.6]	37 [32.4]	0.64
Benzodiazepines	0 [0]	7 [12.9]	4 [8.5]	11 [9.6]	0.34
Quetiapine	0 [o]	0 [o]	2 [4.2]	2 [1.7]	0.23
Medication adherence
Non-pharmacological treatment	2 [15.3]	5 [9.2]	8 [17.0]	15 [13.0]	0.35
Adherent	5 [38.4]	26 [48.1]	17 [36.1]	48 [42.1]
Non-adherent	2 [15–3]	19 [35.1]	17 [36.1]	38 [33.0]
Unknown	4 [30.7]	4 [7.4]	5 [10.6]	13 [11.3]

Data. Mean ± Standard deviation; median (interquartile range); Frequency [percent]
Interpretation. ^a Omega squared = 0.01–0.059 is a low association. 0.06–0.13 is a medium association. ≥0.14 is a large association. ^b Epsilon squared

ISSN: 2523-3106